These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

241 related articles for article (PubMed ID: 19485923)

  • 21. Metformin and vascular protection: a cardiologist's view.
    Libby P
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S117-20. PubMed ID: 14502109
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Comparative risk of major cardiovascular events associated with second-line antidiabetic treatments: a retrospective cohort study using UK primary care data linked to hospitalization and mortality records.
    Zghebi SS; Steinke DT; Rutter MK; Emsley RA; Ashcroft DM
    Diabetes Obes Metab; 2016 Sep; 18(9):916-24. PubMed ID: 27177784
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Metformin. A review of its pharmacological properties and therapeutic use in non-insulin-dependent diabetes mellitus.
    Dunn CJ; Peters DH
    Drugs; 1995 May; 49(5):721-49. PubMed ID: 7601013
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Hypoglycemic therapy in heart disease patients with type 2 diabetes mellitus].
    Cosmi F; Cosmi D
    G Ital Cardiol (Rome); 2010 Jun; 11(6):460-6. PubMed ID: 20922871
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Metformin: An old drug against old age and associated morbidities.
    Salvatore T; Pafundi PC; Morgillo F; Di Liello R; Galiero R; Nevola R; Marfella R; Monaco L; Rinaldi L; Adinolfi LE; Sasso FC
    Diabetes Res Clin Pract; 2020 Feb; 160():108025. PubMed ID: 31954752
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.
    Vaccaro O; Masulli M; Nicolucci A; Bonora E; Del Prato S; Maggioni AP; Rivellese AA; Squatrito S; Giorda CB; Sesti G; Mocarelli P; Lucisano G; Sacco M; Signorini S; Cappellini F; Perriello G; Babini AC; Lapolla A; Gregori G; Giordano C; Corsi L; Buzzetti R; Clemente G; Di Cianni G; Iannarelli R; Cordera R; La Macchia O; Zamboni C; Scaranna C; Boemi M; Iovine C; Lauro D; Leotta S; Dall'Aglio E; Cannarsa E; Tonutti L; Pugliese G; Bossi AC; Anichini R; Dotta F; Di Benedetto A; Citro G; Antenucci D; Ricci L; Giorgino F; Santini C; Gnasso A; De Cosmo S; Zavaroni D; Vedovato M; Consoli A; Calabrese M; di Bartolo P; Fornengo P; Riccardi G; ;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):887-897. PubMed ID: 28917544
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [The effect of metformin on lipid parameters and on cardiovascular risk in patients with type 2 diabetes without statin therapy].
    Kender Z; Groener JB; Reismann P; Kopf S
    Orv Hetil; 2019 Aug; 160(34):1346-1352. PubMed ID: 31423831
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of type 2 diabetes: long-awaited evidence of benefits after blood sugar control.
    Prescrire Int; 1999 Oct; 8(43):147-52. PubMed ID: 11503841
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Practical considerations for the use of sodium-glucose co-transporter type 2 inhibitors in treating hyperglycemia in type 2 diabetes.
    Lam KS; Chow CC; Tan KC; Ma RC; Kong AP; Tong PC; Tsang MW; Chan TM; Tang SC; Lee KK; So WY; Tomlinson B
    Curr Med Res Opin; 2016 Jun; 32(6):1097-108. PubMed ID: 26933918
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Metformin treatment may be associated with decreased levels of NT-proBNP in patients with type 2 diabetes.
    Rosiak M; Postula M; Kaplon-Cieslicka A; Trzepla E; Czlonkowski A; Filipiak KJ; Opolski G
    Adv Med Sci; 2013; 58(2):362-8. PubMed ID: 24327531
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Current role of metformin in treatment of diabetes mellitus type 2].
    Janssen JA
    Ned Tijdschr Geneeskd; 2000 Sep; 144(40):1900-2. PubMed ID: 11045135
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Type 2 diabetes and metformin. First choice for monotherapy: weak evidence of efficacy but well-known and acceptable adverse effects.
    Prescrire Int; 2014 Nov; 23(154):269-72. PubMed ID: 25954799
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Insulin in the early management of diabetic complications.
    Miles JM
    J Assoc Physicians India; 2003 May; 51():501-5. PubMed ID: 12974435
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cardiovascular safety of metformin and sulfonylureas in patients with different cardiac risk profiles.
    Wurm R; Resl M; Neuhold S; Prager R; Brath H; Francesconi C; Vila G; Strunk G; Clodi M; Luger A; Pacher R; Hülsmann M
    Heart; 2016 Oct; 102(19):1544-51. PubMed ID: 27226327
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Thiazolidinediones in type 2 diabetes: a cardiology perspective.
    Khanderia U; Pop-Busui R; Eagle KA
    Ann Pharmacother; 2008 Oct; 42(10):1466-74. PubMed ID: 18698014
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Improving survival with metformin: the evidence base today.
    Scarpello JH
    Diabetes Metab; 2003 Sep; 29(4 Pt 2):6S36-43. PubMed ID: 14502099
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mortality and cardiovascular risk associated with different insulin secretagogues compared with metformin in type 2 diabetes, with or without a previous myocardial infarction: a nationwide study.
    Schramm TK; Gislason GH; Vaag A; Rasmussen JN; Folke F; Hansen ML; Fosbøl EL; Køber L; Norgaard ML; Madsen M; Hansen PR; Torp-Pedersen C
    Eur Heart J; 2011 Aug; 32(15):1900-8. PubMed ID: 21471135
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Metformin as first choice in oral diabetes treatment: the UKPDS experience.
    Holman R
    Journ Annu Diabetol Hotel Dieu; 2007; ():13-20. PubMed ID: 18613325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cardiovascular risks associated with second-line oral antidiabetic agents added to metformin in patients with Type 2 diabetes: a nationwide cohort study.
    Chang YC; Chuang LM; Lin JW; Chen ST; Lai MS; Chang CH
    Diabet Med; 2015 Nov; 32(11):1460-9. PubMed ID: 25970814
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Pharmacologic Management of Type 2 Diabetes Mellitus: Available Therapies.
    Thrasher J
    Am J Med; 2017 Jun; 130(6S):S4-S17. PubMed ID: 28526182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.